{"url_path":"/sec/bblgw/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1419554/0001493152-26-023163-index.html","accession_number":"0001493152-26-023163","cik":"0001419554","ticker":"BBLG","issuer_name":"Bone Biologics Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1419554/0001493152-26-023163-index.html","primary_entity_key":"0001419554","primary_entity_name":"Bone Biologics Corp"},"word_count":47,"has_tables":true,"body_markdown":"**Item\n5. Other Information.**\n\n \n\n**Insider\nTrading Arrangements**\n\n \n\nDuring\nthe three months ended March 31, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement”\nor “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.\n\n \n\n8"}